Organon & Co. reported its fourth quarter and full year 2025 financial results, with full year revenue of $6.2 billion and non-GAAP Adjusted diluted EPS of $3.66. The company also provided full year 2026 guidance for revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion, in-line with 2025 performance.
Key takeaways
Full year 2025 revenue was $6.2 billion, down 3% from 2024.
Full year 2025 diluted EPS was $0.72 and non-GAAP Adjusted diluted EPS was $3.66.
Full year 2025 Adjusted EBITDA was $1.91 billion with a 30.7% margin.
The company expects full year 2026 revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion.
A quarterly dividend of $0.02 per share was declared, payable on March 12, 2026.
As of December 31, 2025, cash and cash equivalents were $574 million and debt was $8.64 billion.